Pediatric atopic dermatitis (AD) presents a considerable challenge, significantly impacting the lives of both children and their families. Shanna Miranti, MPAS, PA-C, a board-certified physician assistant at Riverchase Dermatology and an editorial advisory board member for Dermatology Times, emphasizes that sleep disturbance is a especially debilitating consequence of the condition.

Relentless itch prevents affected children from sleeping, creating a ripple effect of chronic exhaustion, impaired daily functioning, and a diminished quality of life for the entire household. Miranti asserts that restoring sleep is not merely about providing comfort; it is indeed essential for optimal growth, neurodevelopment, and emotional well-being in young patients.

Dermatology clinicians are eagerly anticipating the availability of newer topical therapies with broader pediatric applications. Ruxolitinib cream (Opzelura; Incyte) is expected to receive FDA approval in September 2025 for use in children as young as two years old. This topical Janus kinase (JAK) inhibitor holds the potential to be a transformative treatment option for young patients requiring rapid and effective itch relief.

The ability to utilize targeted therapies with demonstrated efficacy in reducing both inflammation and itch will empower clinicians to intervene earlier and more effectively. This proactive approach promises to improve disease control and enhance the overall well-being of pediatric patients and their families. Miranti’s insights highlight the importance of a dual focus in pediatric AD care: effectively managing symptoms and prioritizing the restoration of healthy sleep patterns.

With promising agents like ruxolitinib possibly becoming available for younger children, dermatology professionals may soon have more powerful tools to address both the immediate discomfort and the long-term health implications of pediatric atopic dermatitis.